Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2007

01-12-2007 | Short communication

A personal viewpoint against the motion that breast cancer patient advocacy groups unfairly distort the cancer budget

Author: Emma L Pennery

Published in: Breast Cancer Research | Special Issue 2/2007

Login to get access

Excerpt

Voluntary sector organizations in the UK have an enviable and successful track record in influencing health care for people affected by breast cancer, and it is entirely refutable that they in any way distort (that is, misrepresent) the cancer budget unfairly in favour of breast cancer. …
Literature
1.
2.
Department of Health: The NHS Cancer Plan: a Plan for Investment, a Plan for Reform. 2000, London, UK: Crown Copyright
3.
4.
5.
6.
Metadata
Title
A personal viewpoint against the motion that breast cancer patient advocacy groups unfairly distort the cancer budget
Author
Emma L Pennery
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1803

Other articles of this Special Issue 2/2007

Breast Cancer Research 2/2007 Go to the issue

Short communication

Oestrogen is bad for patients with breast cancer?

Short communication

Why patient recorded outcomes should be mandatory in and outside clinical trials to guide management of patients with metastatic breast cancer

Short communication

Oxford Overview

Short communication

Short-term presurgical treatment for all?

Short communication

Personalized surgical treatment of breast cancer

Short communication

Adjuvant treatment: the contribution of expression microarrays
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits